92 related articles for article (PubMed ID: 1316101)
1. [Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients].
Suzuki R; Hara M; Shindoh J; Matsumoto S; Noda Y; Gonda H; Tanaka H; Taki F; Takagi K
Gan To Kagaku Ryoho; 1992 May; 19(5):647-52. PubMed ID: 1316101
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of Cepharanthin for preventing leukopenia and thrombocytopenia induced by chemotherapy in breast cancer patient--prospective randomized study].
Suzuki S; Abe R; Nihei M; Kimijima I; Tsuchiya A; Nomizu T
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1195-200. PubMed ID: 2190537
[TBL] [Abstract][Full Text] [Related]
3. [Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer].
Ushiki N; Jobo T; Shimoda T; Kuramoto H; Arai M
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2701-6. PubMed ID: 3415268
[TBL] [Abstract][Full Text] [Related]
4. [Effects of massive administration of cepharanthin on chemotherapy-induced leukopenia].
Asukai K; Kimura A; Gorai I; Uemura T; Minaguchi H
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2583-7. PubMed ID: 2774588
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients.
Saito R; Tsuchiya S; Ishizuka T; Fueki N; Ezawa K; Minato K; Nakano H; Takise A; Kurihara M; Fueki R
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2587-93. PubMed ID: 2559129
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
7. [The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer].
Tsukikawa S; Oikawa H; Satoh T; Morikubo M; Komoriyama H; Hagiwara M; Kanasugi K; Yamaguchi S
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):645-8. PubMed ID: 2108613
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Giaccone G; Huizing M; Postmus PE; ten Bokkel Huinink WW; Koolen M; van Zandwijk N; Vermorken JB; Beijnen JH; Dalesio O; Pinedo HM
Semin Oncol; 1995 Aug; 22(4 Suppl 9):78-82. PubMed ID: 7544030
[TBL] [Abstract][Full Text] [Related]
9. [An early phase II trial combining cisplatin, carboplatin and vindesine in patients with inoperable non-small cell lung cancer].
Haneda H; Koizumi M; Hayashi T
Gan To Kagaku Ryoho; 2000 Feb; 27(2):227-31. PubMed ID: 10700892
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
Hayashi Y; Kato M; Matsuura T; Yamada Y; Adachi S; Ito G; Yamamoto K; Takeuchi T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1455-60. PubMed ID: 2167632
[TBL] [Abstract][Full Text] [Related]
13. [Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Hua XM; Ren XW; Liu FL; Liu Y; Zhang CJ; Li ZJ; Xu L; Liu JY; Liu YG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):621-5. PubMed ID: 15634526
[TBL] [Abstract][Full Text] [Related]
14. [A comparative randomized phase II study of CDDP, CDDP-carboquone (CQ) and CDDP-etoposide as second-line chemotherapy in small cell lung cancer (SCLC)].
Kobayashi K; Hino M; Kurane S; Yano T; Niitani H; Yamano Y; Hasegawa K; Tuboi E
Gan To Kagaku Ryoho; 1989 Feb; 16(2):207-12. PubMed ID: 2537605
[TBL] [Abstract][Full Text] [Related]
15. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
16. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
17. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
18. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
